Drug Delivery Systems' Increasing Role In Patient Outcomes: What's Next?

By Aude Ouensanga and Laure Girard

The drug delivery system (DDS) industry has gone through a tremendous evolution in recent decades as the role of devices and formulations became reinforced in patient care and outcomes.

This evolution has pushed industry players, such as DDS platform developers (i.e., own- IP DDS providers), medical devices CMOs, and pharmaceuticals CDMOs, to develop new strategies to satisfy and anticipate the dynamic needs of their biopharmaceutical customers. The role of DDS providers to pharma evolved from transactional suppliers to innovation partners, and the yet-to-be-met promises of IoMT (Internet of Medical Things) place them more and more at the center of attention.